医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CopilotIQ and Biofourmis Merge to Create the First End-to-End Platform for AI-Driven In-Home Care

2024年10月21日 PM09:00
このエントリーをはてなブックマークに追加


 

NASHVILLE, Tenn. & BOSTON

CopilotIQ, the health tech company helping older Americans with chronic conditions live longer and healthier lives, and Biofourmis, a global technology-enabled care delivery company, delivering in-home care solutions serving enterprise healthcare customers, today announced a strategic merger. The combined company creates the industry’s first AI-driven platform that delivers in-home care across the full spectrum from pre-surgical optimization to acute, post-acute, and chronic care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241021889203/en/

For customers, the combination delivers a single vendor that can provide a best-in-class offering across the entire care continuum and creates a ‘single pane of glass’ solution by which enterprise customers will enjoy observability of patients across the care continuum via one technology integration, one security audit, simplified procurement, and a much better patient experience. Hospitals and payors are struggling with an overwhelming level of complexity and cost to manage multiple point solutions required to deliver the necessary suite of home-based care. This combination provides the first solution that solves these problems.

“Our mission is to redefine the future of healthcare delivery, by extending care to the comfort of patients’ homes, and driving improved health outcomes, at the lowest possible cost to the system,” said David Koretz, CEO of CopilotIQ and Biofourmis, the newly combined entity. “This merger is a major step toward realizing our vision of transforming healthcare from reactive treatment to proactive prevention, and from generalized to deeply personalized, data-driven care.”

Biofourmis’ capabilities in supporting health systems, payors, and life sciences companies’ delivery of complex care for their patients in the home with FDA-cleared algorithms and technology will be expanded further upstream and downstream when combined with CopilotIQ. The combined company will unlock coordinated, convenient, and cost-effective care for patients managing chronic conditions. Further, CopilotIQ’s transformative software suite for driving patient engagement, improving clinician efficiency, and delivering clinical personalization, will be integrated across Biofourmis’ acute and post-acute offerings.

As part of this combination, leading investors from both businesses, including General Atlantic, Openspace Ventures, and Bessemer Venture Partners are investing into the combined business.

About CopilotIQ

CopilotIQ is the creator of the first High Frequency Connected Care platform to transform outcomes for older Americans with chronic conditions. CopilotIQ combines continuous biomarker data, behavioral analytics and US-licensed nursing visits to drive data-driven improvement, coupled with a clinical automation software platform that delivers unprecedented clinical efficiency. The company was named to Fast Company’s list of the World’s Most Innovative Companies of 2024. CopilotIQ is headquartered in Nashville, TN.

About Biofourmis

Biofourmis brings high-quality care and life-changing clinical trials to any person, anywhere. Biofourmis Care enables hospitals, health systems and payors to seamlessly extend care to patients at home across all levels of acuity. Biofourmis Connect streamlines clinical trials with powerful digital capabilities to bring the most effective therapies to market more efficiently. Biofourmis’ data-driven solutions leverage clinical devices, artificial intelligence, and an ecosystem of virtual clinical teams and in-home services to drive quality outcomes, improve operational efficiency, and lower costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241021889203/en/

CONTACT

CopilotIQ

press@copilotiq.com

同じカテゴリーの記事 

  • Asahi Kasei Medical launches Planova™ FG1 next-generation virus removal filter
  • Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
  • Catawba Research Announces Strategic Partnership With PharmaLegacy Laboratories
  • Fujita Health University and BostonGene Expand Access to Genomic Cancer Testing with Tumor Portrait™ at Haneda Clinic
  • HemoHim制造商Kolmar BNH获美国食品药品监督管理局NAI认证